
Science Resources RSS Feeds
|
 |
 |
 |
X-Rays for Early Alzheimer's Disease Detection
June 17, 2009
UPTON, NY - Researchers at the U.S. Department of Energy's (DOE) Brookhaven National Laboratory have demonstrated a new, highly detailed x-ray imaging technique that could be developed into a method for early diagnosis of Alzheimer's disease. The technique has previously been used to look at tumors in breast tissue and cartilage in human knee and ankle joints, but this study is the first to test its ability to visualize a class of miniscule plaques that are a hallmark feature of Alzheimer's disease. Their results will appear in a July 2009 edition of the journal NeuroImage. Scientists have long known that Alzheimer's disease is associated with plaques, areas of dense built-up proteins, in the affected brain. Many also believe that these plaques, called amyloid beta (Aß) plaques after the protein they contain, actually cause the disease. A major goal is to develop a drug that removes the plaques from the brain. However, before drug therapies can be tested, researchers need a non-invasive, safe, and cost-effective way to track the plaques' number and size.
That is no easy task: Aß plaques are extremely small - on the micrometer scale, or one millionth of a meter. And conventional techniques such as computed tomography (CT) poorly distinguish between the plaques and other soft tissue such as cartilage or blood vessels.
"These plaques are very difficult to see, no matter how you try to image them," said Dean Connor, a former postdoctoral researcher at Brookhaven Lab now working for the University of North Carolina. "Certain methods can visualize the plaque load, or overall number of plaques, which plays a role in clinical assessment and analysis of drug efficacy. But these methods cannot provide the resolution needed to show us the properties of individual Aß plaques."
A technique developed at Brookhaven, called diffraction-enhanced imaging (DEI), might provide the extra imaging power researchers crave. DEI, which makes use of extremely bright beams of x-rays available at synchrotron sources such as Brookhaven's National Synchrotron Light Source, is used to visualize not only bone, but also soft tissue in a way that is not possible using standard x-rays. In contrast to conventional sources, synchrotron x-ray beams are thousands of times more intense and extremely concentrated into a narrow beam. The result is typically a lower x-ray dose with a higher image quality.
In this study, researchers from Brookhaven and Stony Brook University used DEI in a high-resolution mode called micro-computed tomography to visualize individual plaques in a mouse-brain model of Alzheimer's disease. The results not only revealed detailed images of the plaques, but also proved that DEI can be used on whole brains to visualize a wide range of anatomical structures without the use of a contrast agent.
The images are similar to those produced by high-resolution magnetic resonance imaging (MRI), with the potential to even exceed MRI pictures in resolution, Connor said. "The contrast and resolution we achieved in comparison to other types of imaging really is amazing," he said. "When DEI is used, everything just lights up."
The radiation dose used for this study is too high to safely image individual A• plaques in humans - the ultimate goal - but the results provide researchers with promising clues.
"Now that we know we can actually see these plaques, the hope is to develop an imaging modality that will work in living humans," Connor said. "We've also now shown that we can see these plaques in a full brain, which means we can produce images from a live animal and learn how these plaques grow."
Funding for this study was provided by the National Institutes of Health, the National Cancer Institute, and Brookhaven Lab's Laboratory Directed Research and Development program. The National Synchrotron Light Source is funded by the Office of Basic Energy Sciences within the DOE Office of Science. How it works
To make a diffraction-enhanced image, x-rays from the synchrotron are first tuned to one wavelength before being beamed at an anatomical structure or slide. As the monochromatic (single wavelength) beam passes through the tissue, the x-rays scatter and refract, or bend, at different angles depending on the characteristics of the tissue. The subtle scattering and refraction are detected by what is called an analyzer crystal, which diffracts, or changes the intensity, of the x-rays by different amounts according to their scattering angles.
The diffracted beam is passed onto a radiographic plate or digital recorder, which documents the differences in intensity to show the interior structural details.
Brookhaven National Laboratory
|
 |

|
A Guide to the Spiritual Dimension of Care for People With Alzheimer s Disease and Related Dementia: More Than Body, Brain, and Breath
by Eileen Shamy (Author)
In this sensitive and informative book, Eileen Shamy, a pioneer of ministry to people with Alzheimer's disease, discusses how pastoral work can help to develop holistic care for those suffering from dementia and related conditions - care which involves understanding of their spiritual as well as physical needs. From her years of experience as a clergywoman working with older people in care settings, the author provides guidelines for pastoral visits to people with dementia, showing how to empathise with, understand and support individuals during a visit. She discusses what constitutes spiritual well-being in individuals and suggests ways in which this can be nurtured. Emphasising the importance of retaining dignity and freedom of choice for people with dementia, she also presents...
|

|
New Science of Alzheimer's Disease / TIME Cover: July 17, 2000, Framed Art Print by TIME Magazine
by barewalls
The most eagerly awaited event in the editorial cycle at TIME Magazine is always the selection of the cover. The best covers capture the zeitgeist of the week while surviving the judgment of history. As browsing this collection of TIME cover art prints shows, TIME is as good a record as any of who and what mattered over the past 80-plus years. And so when TIME captures a person, an event or a trend within its iconic red borders, the magazine is adding that extra dose of significance that no other publication can quite match. That is one reason why the original artwork for more than 800 TIME covers now resides in the National Portrait Gallery in Washington. Thanks to an amazing roster of artists, photographers and graphic designers, from TIME's earliest charcoal drawings of cover subjects...
|

|
The Forgetting - A Portrait of Alzheimer's
Starring: David Hyde Pierce Directed By: Elizabeth Arledge Also With: Elizabeth Arledge (Producer), Doug Quade (Editor), Naomi S. Boak (Producer), Whitney Johnson (Producer)
Studio: Paramount Home Video Release Date: 11/01/2005
|
|
|
Alzheimer’s Disease Chart
by American 3B Scientific
Alzheimer’s Disease Chart Alzheimer’s Disease ChartThis thickly laminated anatomical chart is printed on premium glossy (200 g) UV resistant paper and comes with 2 sided lamination (125 micron, 5.0 Mil) and metal eyelets to make the chart easy to display. It comes in a convenient poster size 50 x 67 cm (20x26’’) and can be written on and wiped off with non permenant markers. The 125 micron lamination ensures the chart does not curl up at the edges and the UV treament ensures the chart does not get a faded yellow color over time.Measurements:50 x 67 cm Weight: 0,15 kgProduct photo may not exactly match the product offered for sale. Please refer to the product description.
|

|
Alzheimer's Disease: A Wilderness Exposed (NCME Video S103)
Also With: Network For Continuing Medical Education (Primary Contributor), Kenneth L. David (Primary Contributor), Allen D. Roses (Primary Contributor), Dennis J. Selkoe (Primary Contributor), Rudolph E. Tanzi (Primary Contributor)
|

|
Natrol Extra Strength ENADA NADH, 5 mg, MicroTablets - 30 ea
by Natrol
The Energizing CoEnzyme. A Patented Formula. The Only Stable NADH. Maximum Bioavailability. Dietary Supplement. Natrol® Enada®'s NADH is a patented dietary ingredient designed for those whose active lifestyles demand the very best. As a coenzyme, NADH plays a key role in the energy production of our cells and neurotransmitter processes.* Natrol offers Enada's NADH - the only stable form of NADH in the marketplace today. This exclusive patented supplement assures maximum bioavailability. *The FDA has not evaluated this statement. This product is not intended to diagnose, treat, cure or prevent disease. If you have or suspect a medical condition, consult your healthcare professional prior to use. NADH (Vegetable source) (reduced 5 nicotinamide...
|

|
Mayo Clinic on Alzheimers Disease
by M.D., Ph.D. Ronald Petersen (Editor)
|
|
|
Alzheimer's s Disease: An Overview.: An article from: Southern Medical Journal
by Ronald C. Hamdy (Author)
This digital document is an article from Southern Medical Journal, published by Southern Medical Association on July 1, 2001. The length of the article is 1102 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.
Citation Details Title: Alzheimer's s Disease: An Overview. Author: Ronald C. Hamdy Publication: Southern Medical Journal (Refereed) Date: July 1, 2001 Publisher: Southern Medical Association Volume: 94 Issue: 7 Page: 661
Distributed by Thomson...
|

|
The Inflammation Pathway from Cholesterol to Aging - Medications and Plants that prevent and treat Aging, Cardiovascular Disease, Osteoporosis, Arthritis, Type-2 Diabetes, Dementia and Alzheimers disease
by Sota Omoigui MD (Author)
|

|
Pharmacogenomics in Drug Discovery and Development (Methods in Molecular Biology)
by Qing Yan (Editor)
Since each human is genetically distinctive, responding differently to disease-causing factors as well as drugs, the field pharmacogenomics arose to develop personalized medicine, or medicine that deals with the complexity of the human body. In Pharmacogenomics in Drug Discovery and Development, leading experts present methodical, state-of-the-art contributions covering topics from individual molecules to systemic diseases, examining both fundamental concepts and advanced technologies. Divided into three sections, the volume begins by exploring cutting-edge technologies used to pursue systems-based pharmacogenomics, followed by extensive chapters on gene-drug interactions and the use of pharmacogenomics in therapeutics of diseases. Comprehensive and up-to-date, Pharmacogenomics...
|
|